Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm
ConclusionsThis study utilised real-world data to simulate a control arm and quantify the clinical effectiveness of genomic testing. The magnitude of survival benefit for patients who had CGP result-led treatments was insufficient to drive an overall survival gain for the entire tested population. Translation of CGP into clinics requires strategies to ensure higher rates of tested patients obtain clinical benefit to deliver on the value proposition of CGP in an advanced cancer population. (Source: Targeted Oncology)
Source: Targeted Oncology - September 5, 2022 Category: Cancer & Oncology Source Type: research

Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma
ConclusionsUnderstanding the mechanisms of resistance with FGFRi is essential to understand sequencing of treatments. In this study, patients received standard chemotherapy in the first line and were fit enough to be considered for subsequent therapy with an FGFRi. Almost half of the patients become ineligible to receive further systemic therapy following progression on FGFRi. As more agents are being introduced, detailed understanding of outcomes following treatment with an FGFRi, including subsequent FGFRi, is essential. (Source: Targeted Oncology)
Source: Targeted Oncology - September 2, 2022 Category: Cancer & Oncology Source Type: research

Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors
ConclusionsImmune checkpoint inhibitors are associated with a high TE risk. Thromboembolism is associated with worsened survival, among other poor outcomes. Further investigation into the mechanism behind immune checkpoint inhibitor-associated TE is needed. (Source: Targeted Oncology)
Source: Targeted Oncology - August 20, 2022 Category: Cancer & Oncology Source Type: research

Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
ConclusionsOur study suggests a prognostic impact of statin use in patients receiving first-line immuno-oncology combinations. The mechanism of this interaction warrants further elucidation. (Source: Targeted Oncology)
Source: Targeted Oncology - August 10, 2022 Category: Cancer & Oncology Source Type: research

Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis
ConclusionIn patients with melanoma or NSCLC, the clinical value of checkpoint inhibitors is evident in both RCTs and real-world settings. Some differences in response or toxicity rates in favor of RWE mainly reflects the inherent difficulties in evaluating these outcomes in RWE studies. (Source: Targeted Oncology)
Source: Targeted Oncology - August 1, 2022 Category: Cancer & Oncology Source Type: research

Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
(Source: Targeted Oncology)
Source: Targeted Oncology - August 1, 2022 Category: Cancer & Oncology Source Type: research

Comment on: BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta ‑Analysis
(Source: Targeted Oncology)
Source: Targeted Oncology - August 1, 2022 Category: Cancer & Oncology Source Type: research

Author ’s Reply to Jia et al.: “BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta‑Analysis”
(Source: Targeted Oncology)
Source: Targeted Oncology - August 1, 2022 Category: Cancer & Oncology Source Type: research

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
AbstractMalignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in many countries, the incidence of malignant pleural mesothelioma failed to decline worldwide. While little progress has been made in malignant pleural mesothelioma diagnosis, bevacizumab at first, then followed by double immunotherapy (nivolumab plus ipilumumab), were all shown to improve survival in large phase III randomized trials. The morphological analysis of the histological subtyping remains the primary indicator for th...
Source: Targeted Oncology - July 30, 2022 Category: Cancer & Oncology Source Type: research

Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry
ConclusionThis large European study describe four different patterns of prostate cancer progression to mCRPC stage. Our results indicate that patient survival becomes comparable after progression to mCRPC, regardless of the diagnosis sequence.Trial RegistrationClinicalTrials.gov identifier NCT02236637; registered September 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - July 16, 2022 Category: Cancer & Oncology Source Type: research

Comment on: “Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy”
(Source: Targeted Oncology)
Source: Targeted Oncology - July 11, 2022 Category: Cancer & Oncology Source Type: research

Author ’s Reply to Şener and Begijanashvili: “Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy”
(Source: Targeted Oncology)
Source: Targeted Oncology - July 11, 2022 Category: Cancer & Oncology Source Type: research

Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria
ConclusionsThere are many trial-ineligible patients in the real world. Nevertheless, the efficacy and safety of ICI-based combination therapy in trial-ineligible patients were non-inferior compared with those of trial-eligible patients. (Source: Targeted Oncology)
Source: Targeted Oncology - July 5, 2022 Category: Cancer & Oncology Source Type: research

Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index
ConclusionIn our series, the outcome of pembrolizumab in pre-treated NSCLC is consistent with the registration trial. Lung Immune Prognostic Index is a readily available tool able to prognosticate outcome, also in PD-L1-high patients. The positive association between irAEs and OS might aid decision making. (Source: Targeted Oncology)
Source: Targeted Oncology - July 4, 2022 Category: Cancer & Oncology Source Type: research

What ’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma
AbstractImmunomodulatory drugs (IMiDs) have become an integral part of therapy for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM). IMiDs bind to cereblon, leading to the degradation of proteins involved in B-cell survival and proliferation. Thalidomide, a first-generation IMiD, has little to no myelosuppressive potential, negligible renal clearance, and long-proven anti-myeloma activity. However, thalidomide ’s adverse effects (e.g., somnolence, constipation, and peripheral neuropathy) and the advent of more potent therapeutic options has led to the drug being less frequently used in many countries,...
Source: Targeted Oncology - June 30, 2022 Category: Cancer & Oncology Source Type: research